• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

Spinal tap needle type impacts the risk of complications

, 26 August 2020/in E-News /by 3wmedia

The type of needle used during a lumbar puncture makes a significant difference in the subsequent occurrence of headache, nerve irritation and hearing disturbance in patients, according to a study by McMaster researchers.
As well, they found the pencil-point atraumatic needle with the better tip design has been available for about 70 years, but few physicians have been using it because they have not been aware of its benefits over the conventional bevelled traumatic needles.
The implications on clinical care are huge, said Dr. Saleh Almenawer, the senior author of the study and a neurosurgeon at Hamilton Health Sciences who worked with a team of researchers at McMaster University including Sheila Singh, Alex Koziarz and Siddharth Nath.
“There is a more than 50 per cent reduction in the occurrence of headaches with the atraumatic needles, and also more than a 50 per cent reduction in patient readmissions and return to emergency rooms for narcotics or blood patches,” said Almenawer.
Post-dural puncture headaches appear in about 35 per cent of patients, sometimes causing debilitating pain that can lead to a return to hospital for painkillers or more invasive treatment.
The study says using atraumatic needles rather than conventional traumatic needles for lumbar punctures is just as effective and results in a significant decrease in complications such as the headaches.
“The two needles differ in how they penetrate the thick membrane, called the dura, surrounding the nerves,” said Almenawer.
He explained that the sharp edges of the tip of a conventional needle cuts its way through, while the tip of an atraumatic needle causes the tissue to dilate and contract around it. The tiny hole left in the dura by the atraumatic needle makes it significantly more difficult for cerebrospinal fluid to leak through, thus diminishing the frequency of headaches, readmissions and treatment.
Atraumatic needles have been around for decades, but their use remains significantly limited, according to the researchers. They also found the atraumatic needles cost the same or up to three times as much as the more conventional type.
“Several surveys from around the world showed that only a fraction of physicians know atraumatic needles exist, and among those even a smaller portion use the atraumatic type,” said Almenawer.
McMasters Universityhttps://tinyurl.com/y9qmsmm6

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:43Spinal tap needle type impacts the risk of complications

Continuous glucose monitors warn of low blood sugar threat

, 26 August 2020/in E-News /by 3wmedia

Continuous glucose monitors (CGM) can protect individuals who have had type 1 diabetes for years and are at risk of experiencing dangerously low blood sugar by increasing their awareness of the symptoms, according to a study.
Episodes of low blood sugar, known as hypoglycemia, are a major barrier to achieving glycemic control for people with diabetes.
The study’s publication comes as the Endocrine Society is developing a multi-year, multi-stakeholder initiative to improve understanding of hypoglycemia and reduce associated costs by implementing strategies to improve prevention and surveillance.
Severe hypoglycemia can cause seizures, loss of consciousness and death. Hypoglycemia linked to the use of insulin was responsible for an estimated $600 million (£510 million) in emergency room visits between 2007 and 2011.
“In individuals who have repeatedly experienced hypoglycemia, the body blunts awareness of symptoms warning of impending episodes,” said the study’s first author, Michael R. Rickels, M.D., M.S., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, Pa. “Wearing a continuous glucose monitor that flags falling glucose levels and has built-in alarms raises recognition of the threat.”
Eleven individuals who had been diagnosed with type 1 diabetes for at least 10 years and had impaired awareness of hypoglycemia received CGMs to monitor their blood sugar levels during an 18-month period. The researchers found the participants became more aware of hypoglycemia events and were less likely to experience severe hypoglycemic episodes after they started using CGMs. However, the body’s defence mechanisms against developing low blood sugar remained impaired. The participants’ hemoglobin A1c levels, which track average blood glucose over time, did not change.
“While the body’s own defences against hypoglycemia did not improve, CGMs filled a valuable need in alerting individuals to oncoming episodes,” Rickels said. “In the absence of physiologic defences against the development of low blood glucose, near-constant use of continuous glucose monitoring may be required to minimize the burden of problematic hypoglycemia in patients with long-standing type 1 diabetes.”
The Endocrine Society and its 18 partners in the Hypoglycemia Quality Collaborative identified reducing and preventing the condition as a high priority.
The Society’s new hypoglycemia quality initiative aims to improve outcomes in individuals with type 2 diabetes. The project’s goals include decreasing the frequency and severity of hypoglycemia episodes, identifying patients who are at high risk in a timely manner, and supporting appropriate clinical interventions that can be administered in doctors’ offices and clinics, avoiding the need for hospitalization. The effort brings together stakeholders from industry, nonprofit organizations and patient groups.

Endocrine Societyhttps://tinyurl.com/yar6t4wb

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:23Continuous glucose monitors warn of low blood sugar threat

Fewer adverse side-effects from partial or reduced breast radiotherapy

, 26 August 2020/in E-News /by 3wmedia

Breast cancer patients reported fewer moderate or marked side effects if they were treated with radiotherapy to part of the breast or a reduced dose to the whole breast, according to new findings from a major study.
The IMPORT LOW study of 2,016 women in 41 centres in the UK has already shown that partial breast and reduced dose radiotherapy was as effective as whole breast radiotherapy in controlling the cancer at five years, and women in the partial breast and reduced dose groups reported fewer side-effects, including less change in the appearance of the breast.
These latest results, which focus predominantly on side-effects affecting the breast and also body image reported during the five years following radiotherapy, show that over half of patients in the study did not report moderate or marked side-effects at any point and that most side-effects reduced over time.
The number of side-effects reported per person were fewer in the partial breast and reduced dose groups compared with the whole breast radiotherapy group.
The IMPORT LOW trial was coordinated by the Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, and funded by Cancer Research UK.
The Institute of Cancer Researchwww.icr.ac.uk/news-archive/women-report-fewer-adverse-side-effects-from-partial-or-reduced-breast-radiotherapy-reveals-major-study

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:30Fewer adverse side-effects from partial or reduced breast radiotherapy

Gentle diagnostics make early-stage heart disease visible

, 26 August 2020/in E-News /by 3wmedia

By no means are only elderly people at risk from heart diseases. Physically active individuals can also be affected, for example if a seemingly harmless flu bug spreads to the heart muscle. Should this remain undetected and if, for example, a builder continues with his strenuous job or an athlete carries on training, this can lead to chronic inflammation and in the worst case even to sudden death.
Professor Eike Nagel and his 12 co-workers at the Institute for Experimental and Translational Cardio Vascular Imaging of Goethe University Frankfurt are developing better ways to predict and diagnose heart diseases. In recent years, the researchers have taken the lead in the development of a procedure that is still very new in heart scans. Nagel explains the advantages: “With the help of magnetic resonance imaging, we can look right inside the heart muscle.” Blood flow to the heart muscle is visualized and shows whether there are any constrictions of the arteries supplying the heart. Experts can also spot whether the heart muscle is scarred, inflamed or displays any other anomalies.
The comparatively fast method makes it possible to examine patients at an early stage and may prevent cardiac insufficiency or even a heart attack. “Diseases such as HIV, kidney damage, rheumatic diseases or tumours often affect the heart either directly or as a side effect of therapy,” says Nagel, describing groups potentially at risk. The cardiologist is convinced: “Nowadays we can treat or even cure so many diseases, but the heart suffers too and this should be carefully monitored as it mostly remains undetected.”
MRI is a non-invasive and gentle examination technique, which is less risky but just as efficient as an examination using a conventional heart catheter, where a thin tube is pushed in the direction of the heart through an artery. Nagel’s research group was recently able to demonstrate this in a large international multi-centre study that was met with international acclaim.
The Institute for Experimental and Translational Cardio Vascular Imaging also has state-of-the-art computer tomography equipment at its disposal that can produce three-dimensional images of the heart. These especially reveal calcium deposits and plaques in the artery walls which could rupture and trigger a sudden heart attack. “This allows us to determine the risk of a heart attack and the need for therapy fast and at an early stage, which can then be non-invasive,” says Nagel. Which technique is best for which patient is one of the research topics Nagel’s group is evaluating. In some patients, both may be needed and the Institute is optimally equipped to answer most aspects of heart disease thanks to its deep insight into the heart.
Nagel finds these rapid advances in imaging over the last decades fascinating: “Nowadays we can spot the slightest changes and literally get a clear picture of the heart’s condition.”
Goethe Universitäthttps://tinyurl.com/ycvjvutf

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:38Gentle diagnostics make early-stage heart disease visible

Study paves the way for better treatment of prostate cancer

, 26 August 2020/in E-News /by 3wmedia

A new study has found a way to identify men with locally advanced prostate cancer who are less likely to respond well to radiotherapy.
Led by Professor Catharine West, The University of Manchester team created a method of selecting prostate cancer patients who would benefit from treatments which target oxygen deficient tumours.
The study was funded by Prostate Cancer UK Prostate Cancer UK with support from the Movember Foundation, and NIHR Manchester Biomedical Research Centre and published in eBiomedicine .
Tumour hypoxia is associated with a poor prognosis in prostate cancer: the lower the oxygen, the greater the resistance to treatment and the more likely a tumour will spread.
The researchers identified a 28-gene signature, which accurately identifies hypoxic tumour tissue in patients with prostate cancer which invades nearby structures
The signature was derived using analysis of human cells in the lab and patient survival data.
The signature was validated using data from across the world in eleven prostate cancer cohorts and a bladder cancer phase III randomized trial of radiotherapy.
According to cancer.net, the 5-year survival rate for most men with local prostate cancer is almost 100%. 98% are alive after 10 years, and 96% live for at least 15 years.
For men diagnosed with prostate cancer that has spread nearby, the 5-year survival is around 70%.

“Until now, there has been no clinically validated method of selecting prostate cancer patients who would benefit from hypoxia modifying treatment
Professor Catharine West„

For men diagnosed with prostate cancer that has spread to other parts of the body, the 5-year survival rate is 29%.
According to Cancer Research UK , over 11,000 still die from the disease every year. In 2014, 13% of all male cancer deaths were from prostate cancer.
Professor West is based at the Manchester Cancer Research Centre- a world renowned partnership between The University of Manchester, The Christie NHS Foundation Trust and Cancer Research UK.
She said: “Ninety percent of prostate cancer patients are diagnosed with localised cancer, which have a highly variable course of disease progression.
“And we know that combining hypoxia-targeting treatment with radiotherapy has been shown to improve local control of tumours and survival of patients in head and neck and bladder cancers.”
She added: “This study has built on work to identify possible ways for measuring hypoxia in prostate cancer using gene signatures.
“Until now, there has been no clinically validated method of selecting prostate cancer patients who would benefit from hypoxia modifying treatment.

University of Manchesterwww.manchester.ac.uk/discover/news/study-paves-the-way-for-better-treatment-of-prostate-cancer/

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:25Study paves the way for better treatment of prostate cancer

New blood pressure app and hardware rivals arm cuff accuracy

, 26 August 2020/in E-News /by 3wmedia

Cuff devices for blood pressure measurement are inconvenient, and mobile device apps for blood pressure measurement that are now being introduced may lack accuracy.
To solve this problem, a team of Michigan State University scientists have created a new app and hardware for smartphones to measure blood pressure with accuracy that may rival arm-cuff devices. The technology also includes a discovery of a more convenient measurement point.
“We targeted a different artery, the transverse palmer arch artery at the fingertip, to give us better control of the measurement,” said Anand Chandrasekhar, MSU electrical and computer engineering doctoral student and the lead author. “We were excited when we validated this location. Being able to use your fingertip makes our approach much easier and more accessible.”
The approach uses two sensors: an optical sensor on top of a force sensor. The sensor unit and other circuitry are housed in a 1 centimetre-thick case attached to the back of the phone. Users turn on the app and press their fingertip against the sensor unit. With their finger on the unit, they hold their phone at heart level and watch their smartphone screen to ensure they’re applying the correct amount of finger pressure.
“A key point was to see if users could properly apply the finger pressure over time, which lasts as long as an arm-cuff measurement,” Ramakrishna Mukkamala, MSU electrical and computer engineering professor and senior author said. “We were pleased to see that 90 percent of the people trying it were able to do it easily after just one or two practice tries.”
Internationally, this device could be a game-changer. While high blood pressure is treatable with lifestyle changes and medication, only around 20 percent of people with hypertension have their condition under control. This invention gives patients a convenient option, and keeping a log of daily measurements would produce an accurate average, discounting an occasional measurement anomaly, Mukkamala added.
The research team will continue to improve accuracy and hopes to pursue more comprehensive testing based on the standard protocol of the Association for the Advancement of Medical Instrumentation. The scientists are already making inroads to build improved hardware. Future iterations could be as thin as 1 millimetre and be part of a standard protective phone case.
Michigan State Universitymsutoday.msu.edu/news/2018/new-blood-pressure-app-and-hardware-rivals-arm-cuff-accuracy/

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:33New blood pressure app and hardware rivals arm cuff accuracy

Canon Medical Systems Corporation receives Green Apple Environmental best practice award

, 26 August 2020/in E-News /by 3wmedia

Canon Medical Systems Corporation (formerly Toshiba Medical) has been awarded the Green Apple Environmental best practice award. The Green Apple awards, a Green Organisation initiative, are part of an annual international campaign to recognise, reward and promote environmental best practice around the world. Canon Medical Systems Corporation was proclaimed Gold Winner in the category Innovation, for its Aquilion ONE Genesis CT scanner. The exclusive awards ceremony was held in the Palace of Westminster, London. Awards were presented in various categories, such as Carbon, Energy Efficiency, Manufacturing and Waste management.

The award winning CT Scanner, Aquilion ONE Genesis, is a smaller and lighter Premium CT system than its predecessors, thus requiring less power. Designed for an installation space of just 19 m2, Aquilion ONE Genesis Edition can be installed in most existing CT rooms, avoiding costly renovations. The open Gantry structure with short bore facilitates access from the front and rear of the gantry.

With regard to the exposure dose for the patients, Aquilion ONE Genesis applies the latest dose reduction technologies and reconstruction algorithms, such as PUREViSION detector technology and FIRST. Its advanced detector technology converts almost 100% of incident X-ray photons for maximum dose efficiency. FIRST is the world’s first fully integrated Iterative Reconstruction Technology in Premium CT, resulting in the lowest dose levels technically achievable today.
 
Henk Zomer, Senior Manager Computed Tomography, says: “It is a great honour for us to receive this award, that shows that Canon Medical’s environmentally innovative products are highly rated internationally. We endeavour to contribute to society with our medical systems while improving the efficiency of medical services, and we vigorously promote our environmental conservation activities.”

“Green Apple Awards” are a prestigious global recognition of environmental best practice issued by “The Green Organisation” – an international, independent, non-profit, non-political, non-activist environment group that was established in 1994 to recognize, reward and promote environmental best practice around the world.

https://eu.medical.canon 
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:40Canon Medical Systems Corporation receives Green Apple Environmental best practice award

Incidence of brain injury in babies estimated for first time

, 26 August 2020/in E-News /by 3wmedia

New research has estimated that each year five babies in every 1,000 born in England suffer a condition or sign linked to brain injury.
The study, conducted by researchers at the Neonatal Data Analysis Unit at Imperial College London and Chelsea and Westminster Hospital NHS Foundation Trust, analysed data on babies born between 2010 and 2015 to assess the number that may have sustained brain injury at or soon after birth.
The researchers used routinely recorded NHS data and so were able to measure the incidence rate of brain injury in newborns without any additional workload for doctors or nurses. Ultimately, this research could lead to a better understanding of how to prevent brain injury in preterm and full term babies.
Dr Chris Gale, lead author and Clinical Senior Lecturer in Neonatal Medicine at Imperial College London and Consultant Neonatologist at Chelsea and Westminster Hospital NHS Foundation Trust, said: “Brain injury at or soon after birth is a serious problem, as it can lead to long-term conditions later in life such as cerebral palsy, blindness, deafness and learning deficits. A proportion of these cases could be avoided.”
Neena Modi, Professor of Neonatal Medicine at Imperial College London and Head of the Neonatal Data Analysis Unit, said: “Before now UK health services did not have a standard definition of brain injury in babies and there has been no systematic collection of data for this purpose.
Professor Modi added: “With colleagues, and in collaboration with the Department of Health, we have devised a practical way to measure the incidence rate of brain injury in babies.”
Published in the journal Archives of Disease in Childhood, the research estimated that 3,418 babies suffered conditions linked to brain injury at or soon after birth in 2015, which equates to an overall incidence rate of 5.14 per 1,000 live births. For preterm births (babies born at or less than 37 weeks) the rate was 25.88 per 1,000 live births in 2015, more than seven times greater than the rate for full term births, which was 3.47 per 1,000 live births.
It is often not known whether a baby has suffered brain injury until later in life. Therefore, the new standardized definition of brain injuries in newborn babies, developed by a group of experts convened by the Department of Health, consists of a range of conditions and signs that are known to be related to brain injury. These include seizures or fits, bleeding within the brain, stroke just before or at birth, infections like meningitis, and damage caused by oxygen deprivation.
The research, commissioned by the Department of Health, is the first to present estimates for the number of babies with brain injuries based on a definition that includes multiple conditions in one measure.
It is also the first time this estimate has been made using data gathered routinely during day-to-day clinical care on neonatal units. The use of routine data required no additional work for clinical staff and provides a valuable way to measure the effectiveness of interventions to reduce brain injury.
As part of a drive to make England a safer place to give birth, the Department of Health has set a target of reducing the number of babies that incur brain injury during or soon after birth by 20% by 2020 and to halve them by 2030. Using these new estimates this equates to lowering the incidence of babies with brain injury to four per 1,000 live births by 2020 and to 2.5 babies per 1,000 live births by 2030.
Overall, the research found that the most common type of condition that contributed to brain injuries was damage caused by lack of oxygen to the brain, called hypoxic ischemic encephalopathy; this is seen mainly in full term babies. For preterm babies, the largest contributor to brain injuries is from bleeding into and around the ventricles of the brain, a condition called periventricular hemorrhage.
Dr Gale added: “Being able to measure how common brain injuries are allows health professionals and researchers to focus on reducing these devastating conditions. This includes the consistent use of treatments that reduce the risk of brain injuries in preterm infants, such as steroids and magnesium sulphate given to the mother before birth.
“This measure will also help us to evaluate other interventions, for example, making sure that as many preterm babies as possible are born at hospitals with advanced neonatal services on site, which we know reduces the risk of brain injury.
“The next step is to use routine data to understand the long-term effects of these conditions on the children and their families.”

Imperial College Londonhttps://tinyurl.com/ycnbqzlo

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:20Incidence of brain injury in babies estimated for first time

New technology for measuring brain blood flow with light

, 26 August 2020/in E-News /by 3wmedia

Biomedical engineers at the University of California, Davis, have developed a new technique for measuring blood flow in the human brain, which could be used in patients with stroke or traumatic brain injury, for example. The new technique, based on conventional digital camera technology, could be significantly cheaper and more robust than prior methods.
“Our setup is very promising, and the cost should be lower,” said Wenjun Zhou, a postdoctoral researcher working with Vivek Srinivasan, associate professor at the UC Davis Department of Biomedical Engineering.
If you shine a light into a cloudy solution, light particles, or photons, will be scattered in different directions. An experimental technique called diffuse correlation spectroscopy, or DCS, uses essentially this approach to look inside someone’s skull. Laser light is shined on the head; as photons from the laser pass through the skull and brain, they are scattered by blood and tissue. A detector placed elsewhere on the head, where the photons make their way out again, picks up the light fluctuations due to blood motion. These fluctuations provide information about blood flow.
The light signal is very weak, and the further it passes through the skull and brain tissue, the weaker it gets. So DCS requires a number of very sensitive, expensive single photon counting detectors. Boosting the light going in risks burning the patient’s skin.
Zhou and Srinivasan took a different approach, based on the fact that overlapping light waves will reinforce or cancel each other out, like overlapping ripples on a pond.
They first split the light beam into “sample” and “reference” paths. The sample beam goes into the patient’s head and another, stronger, reference beam is routed so that it reconnects with the sample beam before going to the detector. This boosts the signal, meaning that instead of needing about 20 photon-counting detectors that cost a few thousand dollars each, the researchers could use a single CMOS-based digital camera chip for a fraction of the price.
“The strong reference light enhances the weaker signal from the sample,” Zhou said.
They call the method interferometric diffusing wave spectroscopy, or iDWS. An added advantage is that they do not need to turn off the room lights while making measurements with iDWS, Zhou said. Eventually, they may even be able to monitor brain blood flow outdoors, under bright sunlight.
So far, the team has tested their device by making brain recordings from volunteers in the laboratory. They are working with Dr. Bruce Lyeth and Dr. Lara Zimmermann in the UC Davis Department of Neurological Surgery to validate and adapt the technology for eventual use in neurocritical care. UC Davis has applied for a provisional patent on the technology.
Other authors on the paper are graduate student Oybek Kholiqov and postdoctoral researcher Shau Poh Chong. Srinivasan also holds an appointment at the Department of Ophthalmology and Vision Science, UC Davis School of Medicine. The work was funded by grants from the National Institutes of Health.

University of California – Daviswww.ucdavis.edu/news/new-technology-measuring-brain-blood-flow-light

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:28New technology for measuring brain blood flow with light

Scientists unleash power of genetic data to identify disease risk

, 26 August 2020/in E-News /by 3wmedia

Massive banks of genetic information are being harnessed to shed new light on modifiable health risks that underlie common diseases.
University of Queensland researchers have pioneered a method to integrate data from multiple large-scale studies to assess risk factors such as body mass index (BMI) and cholesterol levels, and their association with diseases including type two diabetes and heart disease.
Professor Jian Yang, from UQ’s Institute for Molecular Bioscience and Queensland Brain Institute, said the new method was more powerful than earlier techniques and enabled scientists to identify risk associations that were difficult to detect in smaller samples.
“Identifying new risk factors provides an avenue to look at diseases from a different angle,” Professor Yang said.
“For example, LDL-cholesterol is known to be a risk factor for cardiovascular disease, but we were surprised to see that it actually lowers your risk of type two diabetes.
“Discoveries like this could have significant implications for medical research, the pharmaceutical industry and public health policy.”
The study looked at seven known health risk factors and more than 30 common diseases, in genetic data from more than 400,000 people.
Professor Yang said the method identified 45 potentially causal associations between health risk factors and diseases.
“Some of these associations – such as the link between BMI and type 2 diabetes and cardiovascular disease – have already been confirmed in randomized controlled trials, which validates our methods,” Professor Yang said.
“Others identified in this study provide candidates for prioritization in future trials, and fundamental knowledge to understand the biology of the diseases.
“For example, we identified a highly significant risk effect of HDL-cholesterol on age-related macular degeneration.”
Professor Yang said the method was particularly valuable where clinical trials to investigate associations would be impractical or even unethical.
“Years of education is one trait we looked at in the study, and it had a protective effect against most diseases, particularly for Alzheimer’s and coronary artery disease – but it is something that needs to be carefully investigated in the future,” Professor Yang said.
University of Queenslandhttps://tinyurl.com/y9lfo963

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:36:192020-08-26 14:36:35Scientists unleash power of genetic data to identify disease risk
Page 201 of 228«‹199200201202203›»

Latest issue of International Hospital

April 2024

9 May 2025

New open-source AI platform launched for global infectious disease surveillance

9 May 2025

Fujifilm launches advanced ELUXEO 8000 endoscopy system in Europe

5 May 2025

Siemens Healthineers unveils helium-independent MRI system for radiotherapy

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription